Monday, May 20, 2013
Four years after launching a strategic venture fund, the Merck
Serono S.A. unit of Merck
KGaA is making a long-term commitment with an infusion of €60 million ($77.8 million).
While the fund's focus will
remain on seed and series A deals, the cash injection will enable later-stage
investments, with a proviso - an asset must be sufficiently differentiated and
fit Merck Serono's focus in cancer, neurodegenerative, immunology, endocrinology
and fertility indications.